Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20032245 | 0.98 | EPHX1 (0.37) | EPHX1EPHX2HCAR2 | |
| SCHEMBL5683395 | 0.98 | EPHX1 (0.37) | EPHX1EPHX2HCAR2 | |
| SCHEMBL20031997 | 0.98 | EPHX1 (0.37) | EPHX1EPHX2HCAR2 | |
| SCHEMBL20031998 | 0.98 | EPHX1 (0.37) | EPHX1EPHX2HCAR2 | |
| SCHEMBL23743045 | 0.95 | — | — | |
| Ammonia Solution, Strong SCHEMBL27350163 | 0.93 | EPHX1 (0.37) | EPHX1EPHX2HCAR2 | |
| SCHEMBL12984443 | 0.90 | — | — | |
| SCHEMBL23697388 | 0.90 | EPHX1 (0.34) | EPHX1EPHX2HCAR2 | |
| SCHEMBL14704905 | 0.82 | HCAR2 (0.38) | EPHX1EPHX2HCAR2 | |
| SCHEMBL2982280 | 0.82 | EPHX1 (0.36) | EPHX1EPHX2HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12202826-B2 | N-pyridinyl acetamide derivatives as inhibitors of the Wnt signaling pathway | REDX PHARMA PLC (GB) | 2025-01-21 | — | — | US | disclosed |
| CN-119265580-A | Preparation method of ticagrelor intermediate 4, 6-dichloro-2-propylsulfanyl-5-aminopyrimidine | 浙江工业大学 | 2025-01-07 | — | — | CN | disclosed |
| CN-117686599-A | Analysis and detection method for nitrosamine impurities in ticagrelor | 常州制药厂有限公司 | 2024-03-12 | — | — | CN | disclosed |
| US-20230365549-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY | REDX PHARMA PLC (GB) | 2023-11-16 | — | — | US | disclosed |
| US-11643408-B2 | N-pyridinyl acetamide derivatives as inhibitors of the WNT signaling pathway | REDX PHARMA PLC (GB) | 2023-05-09 | — | — | US | disclosed |
| EP-3204378-B3 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALLING PATHWAY | REDX PHARMA PLC (GB) | 2022-05-25 | — | — | EP | disclosed |
| US-20210046076-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY | REDX PHARMA PLC (GB) | 2021-02-18 | — | — | US | disclosed |
| US-10793560-B2 | N-pyridinyl acetamide derivatives as inhibitors of the WNT signaling pathway | REDX PHARMA PLC (GB) | 2020-10-06 | — | — | US | disclosed |
| CN-110392833-A | The method for treating nervous disorders | 优曼尼蒂治疗公司 | 2019-10-29 | — | — | CN | disclosed |
| EP-3204378-B1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALLING PATHWAY | REDX PHARMA PLC (GB) | 2019-07-10 | — | — | EP | disclosed |
| US-20180319788-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY | REDX PHARMA PLC (GB) | 2018-11-08 | — | — | US | disclosed |
| US-20170275276-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY | REDX PHARMA PLC (GB) | 2017-09-28 | — | — | US | disclosed |
| EP-3204378-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALLING PATHWAY | Redx Pharma PLC (GB) | 2017-08-16 | — | — | EP | disclosed |
| WO-2016055786-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALLING PATHWAY | REDX PHARMA PLC (GB) | 2016-04-14 | — | — | WO | disclosed |
| CN-102786485-B | 2-substituted-2H-1,2,3-triazole derivative and preparation method thereof | ABA CHEMICALS CORP | 2014-11-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12202826-B2 | N-pyridinyl acetamide derivatives as inhibitors of the Wnt signaling pathway | WNT1, WNT3, CTNNB1 | EPHX1 4168/4885EPHX2 4558/4885HCAR2 1568/4885 |
| US-10793560-B2 | N-pyridinyl acetamide derivatives as inhibitors of the WNT signaling pathway | WNT1, WNT3, CTNNB1 | EPHX1 4334/4885EPHX2 4646/4885HCAR2 1531/4885 |
| US-20230365549-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY | WNT1, WNT3, CTNNB1 | EPHX1 4168/4885EPHX2 4558/4885HCAR2 1568/4885 |
| US-20180319788-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY | WNT1, WNT3, CTNNB1 | EPHX1 4334/4885EPHX2 4646/4885HCAR2 1531/4885 |
| US-20170275276-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY | WNT1, WNT3, CTNNB1 | EPHX1 4334/4885EPHX2 4646/4885HCAR2 1531/4885 |
| US-20210046076-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY | WNT1, WNT3, CTNNB1 | EPHX1 4168/4885EPHX2 4558/4885HCAR2 1568/4885 |
| US-11643408-B2 | N-pyridinyl acetamide derivatives as inhibitors of the WNT signaling pathway | WNT1, WNT3, CTNNB1 | EPHX1 4168/4885EPHX2 4558/4885HCAR2 1568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.